Full Press Release Details
Charles River Laboratories Announces Governance
Strategic Review to Enhance Long-Term Stockholder
- Board Approves Appointment
of Four New Directors -
- Strategic Planning and Capital
Allocation Committee of the Board
to Conduct Comprehensive Strategic
Review of the Company's Business -
- Enters into Cooperation Agreement
with Elliott Investment Management -
WILMINGTON, MA, May 7, 2025 - Charles River Laboratories
International, Inc. (NYSE: CRL) today announced that four new directors will join its Board of Directors and that four long-time members
of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees
and a strategic review of the Company's business focused on enhancing long-term value for shareholders.
Charles River's Board of Directors has agreed to appoint four
new directors, Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves, who will join the Board effective following the 2025 Annual Meeting
of Shareholders to be held on May 20, 2025. Four existing directors, Robert Bertolini, Deborah Kochevar, George Massaro and Richard Wallman,
have announced their intentions to not seek re-election at the end of their previously elected terms at the 2025 Annual Meeting. Following
the new director appointments, the Company's Board will consist of eleven directors, nine of whom will be independent.
As part of these actions, Martin Mackay, Ph.D. will serve as Lead Independent
Director, Nancy Andrews, M.D., Ph.D. will serve as Chair of the Corporate Governance and Nominating Committee, and Reshema Kemps-Polanco
will serve as Chair of the Compensation Committee. Virginia Wilson will remain Chair of the Audit Committee. Additionally, Steven Barg,
Mark Enyedy and Paul Graves will join the Strategic Planning and Capital Allocation Committee, with Paul Graves serving as Chair. The
Board will also establish a New Approach Methodologies and Science Committee (NAMS) through the combination of the Science and Technology
and Responsible Animal Use committees, which will be chaired by Craig Thompson, M.D.
The Board, through the Strategic Planning and Capital Allocation Committee,
will conduct a comprehensive strategic review and evaluation of Charles River's business and prospects, including an examination
of various alternatives to enhance long-term stockholder value. The committee will present its recommendations to the full Board upon
completion of its review.
Charles River also announced a Cooperation Agreement with Elliott Investment
Management L.P., Charles River's largest investor, under which Elliott has agreed to customary standstill, voting, confidentiality,
and other provisions.
James C. Foster, Chair, President and Chief Executive Officer of Charles
River Laboratories said, "Charles River has a long track record of taking actions to navigate dynamic market conditions and position
the Company for growth. The initiatives announced today are a continuation of this effort for the benefit of all our stakeholders. We
are pleased to welcome Steven Barg, Abe Ceesay, Mark Enyedy, and Paul Graves to the Board, whose seasoned industry expertise, strong operational
and leadership experience, and fresh perspectives will add significant value as we continue to execute our initiatives to optimize our
operating performance and drive efficiencies across Charles River's portfolio, and enhance long-term shareholder value."
Mr. Foster continued, "We would also like to extend our gratitude
to Robert Bertolini, Deborah Kochevar, George Massaro and Richard Wallman for their long-standing service to the Charles River Board.
Their leadership, strategic counsel, and many contributions over the years have been instrumental in the growth of Charles River to become
a leading global partner for the discovery and development of life-changing novel drugs and therapeutics."
"We also welcome the opportunity to collaborate with Elliott
Investment Management as we undertake these initiatives. They have deep experience in the healthcare space and have shown confidence in
and commitment to enhancing the long-term potential of Charles River. Our Board and management look forward to working together to continue
to position Charles River as the scientific partner of choice, poised to capture the significant opportunities ahead of us, and to deliver
exceptional value for all our stakeholders," Mr. Foster concluded.
Elliott Partner Marc Steinberg said, "Charles River plays a mission-critical
role in biomedical research and development, and we have long admired the Company's market-leading capabilities and strong competitive
positioning under Jim Foster's leadership. We believe that the Company's current value is significantly disconnected from
its underlying potential, and as Charles River's largest investor, we see a substantial opportunity to unlock that value. The changes
announced today - including the new additions to the Board and the undertaking of a comprehensive strategic review - are the
right ones, and we look forward to continuing our constructive partnership with Jim Foster and the Charles River Board and leadership
The Cooperation Agreement with Elliott will be filed in a Current Report
on Form 8-K with the Securities and Exchange Commission.
Gordon Dyal & Co. Advisory Group LP is serving as financial advisor
and Davis Polk & Wardwell LLP is serving as legal counsel to Charles River.
New Board Member Biographies
Steven Barg is Global Head of Engagement at Elliott Investment
Management L.P. and brings significant M&A and capital markets expertise, as well as public board experience in the CDMO/CRO space.
Prior to joining Elliott in February of 2020, Mr. Barg spent 30 years in investment banking, most recently as a Participating Managing
Director at Goldman Sachs. Mr. Barg established and led what became the firm's Global Activism and Shareholder Advisory practice; founded
and led the M&A Capital Markets practice; and ran Asian Equity Capital Markets in Hong Kong. In addition, Mr. Barg served on both
the Asian and Global Equity Commitments Committees and was Global Head of Diversity for the Investment Banking Division. Prior to joining
Goldman Sachs, Mr. Barg served as a Managing Director in Equity Capital Markets at UBS and Credit Suisse, with postings in New York, Hong
Mr. Barg previously served on the boards of Cardinal Health and Catalent.
He holds an M.B.A. from the Stanford University Graduate School of Business and a B.A. from Wesleyan University. In addition, Mr. Barg
was a Henry Luce Scholar in Hong Kong and a Coro Fellow in Public Affairs in New York.
Abe Ceesay is Chief Executive Officer of Rapport Therapeutics
and has nearly two decades of executive and public company biopharmaceutical industry experience. Prior to joining Rapport, he served
as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously Chief Executive Officer of Tiburio Therapeutics.
Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx
Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly
Mr. Ceesay serves on the boards of Rapport Therapeutics, Pacira BioSciences,
and Life Science Cares, as well as on the Board of Trustees at The Museum of Science in Boston. He holds an M.B.A. from Suffolk University's
Sawyer School of Management and a B.A. from Ithaca College.
Mark Enyedy has nearly three decades of combined general management,
business development and legal experience in the biotechnology industry. He brings significant M&A and capital markets experience,
as well as public healthcare board experience. He most recently served as the President and Chief Executive Officer of ImmunoGen from
2016 until it was acquired by AbbVie in 2024. Mr. Enyedy joined ImmunoGen from Shire plc, where he served as Executive Vice President
and Head of Corporate Development, leading the company's strategy, M&A, and corporate planning functions and providing commercial
oversight for the company's pre-Phase 3 portfolio. Previously, Mr. Enyedy served as Chief Executive Officer and a director of Proteostasis
Therapeutics, following 15 years at Genzyme Corporation in diverse roles, most recently as President of the transplant, oncology, and
multiple sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an Associate with the Boston law firm Palmer & Dodge.
Mr. Enyedy serves on the board of BioMarin and previously served on
the boards of ImmunoGen, Ergomed plc, LogicBio Therapeutics, Akebia Therapeutics, Fate Therapeutics, and Keryx Biopharmaceuticals, as
well as The American Cancer Society of Eastern New England and The Biotechnology Innovation Organization. Mr. Enyedy holds a J.D. from
Harvard Law School and a B.S. from Northeastern University.
Paul Graves is Chief Executive Officer of Rio Tinto Lithium
(previously Arcadium Lithium until it was acquired by Rio Tinto in March 2025) and brings significant executive leadership and public
company board experience, as well as investment banking and M&A expertise. Previously, Mr. Graves served as Chief Executive Officer
of Livent and was an integral part of the merger with Allkem that created Arcadium Lithium. Previously, Mr. Graves was the Executive Vice
President and Chief Financial Officer of FMC Corporation. Before joining FMC, he was a partner at Goldman Sachs, serving in a variety
of roles, including as Head of Natural Resources for Asia and Global Head of Chemical Investment Banking.
Mr. Graves served on the board of Arcadium Lithium until its acquisition
by Rio Tinto, and also previously served on the boards of Livent and Lydall. He holds a B.A. from Nottingham Trent University.
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate,"
"believe," "expect," "intend," "will," "would," "may," "estimate,"